ISRG falls as FDA flags stapler issue and Wall Street trims targets
Intuitive Surgical shares are sliding as investors react to a newly highlighted FDA early alert tied to certain Intuitive curved-tip staplers and a “remove from use or sale” customer action. The pullback is also being amplified by fresh valuation/expectations pressure following a recent UBS price-target cut to $550 while keeping a Neutral rating.
1. What’s moving the stock
Intuitive Surgical (ISRG) is down today as the market digests an FDA early alert tied to an Intuitive Surgical stapler issue. The FDA said Intuitive sent affected customers a March 11, 2026 letter recommending certain curved-tip staplers be removed from where they are used or sold, putting a product-quality/regulatory headline back at the center of the tape. (fda.gov)
2. Wall Street tone adds pressure
The decline is also landing in a tape where investors have been sensitive to premium-multiple med-tech names, making negative catalysts hit harder. UBS recently maintained a Neutral rating while cutting its price target to $550 from $570, reinforcing the idea that upside may be more incremental near term even with strong long-run positioning. (benzinga.com)
3. What to watch next
Key swing factors are whether the stapler situation remains contained to specific products and customer actions, and whether there are follow-on updates that broaden the scope or timeline. Traders will also watch for any commentary on commercial impact, including whether hospitals delay purchases, change utilization, or incur additional servicing/training steps that could weigh on margins in coming quarters. (fda.gov)